Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Friday, March 10, 2023Alnylam Pharmaceuticals Inc the leading RNAi therapeutics company and Medison Pharma Medison a global pharma company focused on providing access to highly innovative therapies for patients in international markets have announced an expansion of their...
IIVS and Toxys Enter into Agreement to Offer ToxTracker® for In Vitro Genetic Toxicity Evaluation
Thursday, March 09, 2023The Institute for In Vitro Sciences IIVS and Toxys have entered into a license agreement that allows IIVS to offer the ToxTracker assay ToxTracker is an innovative in vitro assay allowing identification of the genotoxic and potentially carcinogenic p...
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
Thursday, March 09, 2023CNS Pharmaceuticals Inc a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system today announced that the first patient in Switzerland has been enrolled...
Vetter Strengthens Worldwide Commitment to Sustainable Business Practices
Wednesday, March 08, 2023Vetter has recently become a participant of the UN Global Compact Network UN GC The globally operating Contract Development and Manufacturing Organization CDMO is one of the pioneers in the industry regarding responsible sustainable and transparent b...
Protect Pharmaceutical Corp. Announces New President Ali Yildiz
Wednesday, March 08, 2023Protect Pharmaceutical Corp OTCPRTT announces the change of control of the Preferred series A shares and the appointment of a new president Ali Yildiz Aetsoft as previously announced has been divested from the company Mr Yildiz brings a wealth of kno...
Abacus Medicine Pharma Services and AddMedica Sign Partnership Agreement for the Distribution of Siklos® in Benelux
Tuesday, March 07, 2023Abacus Medicine Pharma Services AMPS and AddMedica are proud to announce the signing of a partnership agreement for the marketing and distribution of Siklos in Benelux Siklos mg and mg filmcoated tablets are indicated for the treatment of adults adol...
MIMETAS Launches Ready-to-Use 3D Adult Stem Cell Organoid Tubules
Tuesday, March 07, 2023MIMETAS a leading company in the field of organonachipbased disease models announces that it has launched its Adult Stem Cell ASCderived tubular organoids in an assayready format As part of its OrganoReady product line MIMETAS offers two organoidbase...
Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress
Tuesday, March 07, 2023Cidara Therapeutics Inc a biotechnology company developing longacting therapeutics designed to help improve the standard of care for patients facing serious diseases presented preclinical data on a CDtargeting drugFc conjugate DFC candidate CBO from...
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI
Monday, March 06, 2023Eisai Co Ltd and Biogen Inc announced today that the US Food and Drug Administration FDA has accepted Eisais supplemental Biologics License Application sBLA for LEQEMBI mgmL injection for intravenous use supporting the conversion of the accelerated...
Participants Dosed on Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa
Monday, March 06, 2023MiGenTra a Berlinbased healthcare transforming company reported today that the first participants in a Phase clinical trial for Minapharm Pharmaceuticals adalimumab biosimilar candidate brand name Adessia were dosed on February in Germany This fol...
